治疗肥胖的新药氯卡色林  

Lorcaserin,a new agent for the treatment of obesity

作　　者：石卫峰[1] 归成[1] 李晓宇[1] 刘皋林[1] 

机构地区：[1]上海交通大学附属第一人民医院药剂科,上海200080

出　　处：《中国新药杂志》2014年第2期127-129,133,共4页Chinese Journal of New Drugs

摘　　要：肥胖已经成为一个世界性的问题,额外的体重可增加高血压、糖尿病、高脂血症、卒中、心脏病、骨关节炎的风险。氯卡色林(lorcaserin)是一种口服有效的选择性5-羟色胺2C受体激动剂,盐酸氯卡色林(lorcaserin hydrochloride,BelviqTM)于2012年6月27日获美国FDA批准上市,用于治疗肥胖症。临床研究表明,该药可有效降低肥胖和超重患者的体重,改善肥胖相关的代谢指标,且耐受性良好。现就其作用机制、药动学、临床疗效及安全性等做一综述。Obesity has become a worldwide problem since the extra weight can increase the risk of hypertension,diabetes,hyperlipidemia,stroke,heart disease,and osteoarthritis.Lorcaserin is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity.It had been approved for marketing in US by FDA on 27 June in 2012.In clinical studies,lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters,and it is well tolerated.Pharmacological mechanism,pharmacokinetics,clinical efficacy and safety of lorcaserin had been summarized in this paper.

关 键 词：氯卡色林 5-羟色胺受体激动剂 肥胖 超重 减肥 

分 类 号：R977[医药卫生—药品]